BIOLARGO, Inc. (BLGO) intrinsic value & 10-year financials
BIOLARGO, Inc. (BLGO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 44.6% a year to $7.8M, with an average return on invested capital of 51.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.07
- Revenue (FY2025)
- $7.8M
- Revenue growth (10-yr CAGR)
- 44.6%
- ROIC (10-yr avg)
- 51.5%
- Free cash flow (FY2025)
- —
BLGO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.8M | -$15.2M | — | — | -191.3% | -262.4% |
| FY2024 | $17.8M | -$4.3M | — | — | -24.4% | -67.6% |
| FY2023 | $12.2M | -$4.6M | — | — | -37.4% | -104.9% |
| FY2022 | $5.9M | -$5.1M | — | — | -91.6% | -118.4% |
| FY2021 | $2.5M | -$6.9M | — | — | -254.3% | -164.0% |
| FY2020 | $2.4M | -$9.7M | — | — | -311.8% | -945.0% |
| FY2019 | $1.9M | -$11.4M | — | — | -359.8% | 853.4% |
| FY2018 | $1.4M | -$10.7M | — | — | -470.1% | 484.6% |
| FY2017 | $516.0K | -$9.5M | — | -$4.3M | -1142.4% | 1239.7% |
| FY2016 | $281.1K | -$8.1M | — | — | -1755.5% | -400.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIOLARGO, INC. is a consistent compounder, expanding top-line revenue at 44.6% annually over the past decade.
BIOLARGO, INC. has historically struggled to out-earn its cost of capital, averaging just -28.3% ROIC.
BIOLARGO, INC. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BIOLARGO, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment.